Gotham Asset Management LLC Acquires 596 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Gotham Asset Management LLC grew its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 4.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,905 shares of the medical equipment provider’s stock after acquiring an additional 596 shares during the quarter. Gotham Asset Management LLC’s holdings in Lantheus were worth $1,154,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of LNTH. Kestra Investment Management LLC bought a new stake in shares of Lantheus in the fourth quarter valued at approximately $27,000. Summit Securities Group LLC bought a new stake in shares of Lantheus in the fourth quarter valued at approximately $37,000. UMB Bank n.a. boosted its position in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after acquiring an additional 134 shares during the period. Parkside Financial Bank & Trust boosted its position in shares of Lantheus by 49.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock valued at $76,000 after acquiring an additional 280 shares during the period. Finally, 1620 Investment Advisors Inc. bought a new stake in shares of Lantheus in the fourth quarter valued at approximately $125,000. 99.06% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on LNTH. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a research report on Thursday, May 8th. Truist Financial reduced their target price on Lantheus from $127.00 to $117.00 and set a “buy” rating for the company in a research report on Thursday, May 8th. Finally, B. Riley reduced their target price on Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research report on Friday, March 21st. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $132.67.

Lantheus Price Performance

Shares of LNTH stock opened at $81.24 on Friday. The stock has a fifty day moving average price of $97.11 and a 200 day moving average price of $93.20. Lantheus Holdings, Inc. has a one year low of $75.00 and a one year high of $126.89. The stock has a market cap of $5.62 billion, a P/E ratio of 13.52 and a beta of 0.23.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. During the same quarter in the prior year, the company earned $1.69 earnings per share. The business’s revenue was up .8% compared to the same quarter last year. Equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insiders Place Their Bets

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares of the company’s stock, valued at $11,445,207.20. This represents a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 63,109 shares of company stock worth $6,016,046 over the last three months. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.